TScan Therapeutics (TCRX) Competitors $0.96 -0.04 (-3.69%) Closing price 04:00 PM EasternExtended Trading$1.00 +0.04 (+4.35%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TCRX vs. FHTX, LENZ, IKT, RNAC, and VYGRShould you buy TScan Therapeutics stock or one of its competitors? MarketBeat compares TScan Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TScan Therapeutics include Foghorn Therapeutics (FHTX), LENZ Therapeutics (LENZ), Inhibikase Therapeutics (IKT), Cartesian Therapeutics (RNAC), and Voyager Therapeutics (VYGR). These companies are all part of the "pharmaceutical products" industry. TCRX vs. FHTXTCRX vs. LENZTCRX vs. IKTTCRX vs. RNACTCRX vs. VYGRHow does TScan Therapeutics compare to Foghorn Therapeutics?Foghorn Therapeutics (NASDAQ:FHTX) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment. Do institutionals & insiders believe in FHTX or TCRX? 61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 7.6% of Foghorn Therapeutics shares are owned by insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer FHTX or TCRX? In the previous week, Foghorn Therapeutics had 1 more articles in the media than TScan Therapeutics. MarketBeat recorded 1 mentions for Foghorn Therapeutics and 0 mentions for TScan Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.78 beat TScan Therapeutics' score of 0.00 indicating that Foghorn Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Foghorn Therapeutics Positive TScan Therapeutics Neutral Which has higher earnings & valuation, FHTX or TCRX? Foghorn Therapeutics has higher revenue and earnings than TScan Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFoghorn Therapeutics$30.91M6.84-$74.28M-$1.16N/ATScan Therapeutics$9.14M6.89-$129.77M-$0.96N/A Do analysts recommend FHTX or TCRX? Foghorn Therapeutics currently has a consensus price target of $11.43, indicating a potential upside of 217.46%. TScan Therapeutics has a consensus price target of $6.00, indicating a potential upside of 522.99%. Given TScan Therapeutics' higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than Foghorn Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Foghorn Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88TScan Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more risk and volatility, FHTX or TCRX? Foghorn Therapeutics has a beta of 2.97, suggesting that its share price is 197% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Is FHTX or TCRX more profitable? Foghorn Therapeutics has a net margin of -266.88% compared to TScan Therapeutics' net margin of -1,360.61%. Foghorn Therapeutics' return on equity of 0.00% beat TScan Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Foghorn Therapeutics-266.88% N/A -35.38% TScan Therapeutics -1,360.61%-91.94%-50.15% SummaryFoghorn Therapeutics beats TScan Therapeutics on 12 of the 17 factors compared between the two stocks.How does TScan Therapeutics compare to LENZ Therapeutics?TScan Therapeutics (NASDAQ:TCRX) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings. Do analysts rate TCRX or LENZ? TScan Therapeutics currently has a consensus target price of $6.00, indicating a potential upside of 522.99%. LENZ Therapeutics has a consensus target price of $29.80, indicating a potential upside of 348.12%. Given TScan Therapeutics' higher possible upside, analysts plainly believe TScan Therapeutics is more favorable than LENZ Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33LENZ Therapeutics 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is TCRX or LENZ more profitable? LENZ Therapeutics has a net margin of -519.30% compared to TScan Therapeutics' net margin of -1,360.61%. LENZ Therapeutics' return on equity of -46.82% beat TScan Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TScan Therapeutics-1,360.61% -91.94% -50.15% LENZ Therapeutics -519.30%-46.82%-43.32% Which has more risk & volatility, TCRX or LENZ? TScan Therapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Do institutionals & insiders believe in TCRX or LENZ? 82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 6.3% of TScan Therapeutics shares are owned by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has higher earnings and valuation, TCRX or LENZ? LENZ Therapeutics has higher revenue and earnings than TScan Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTScan Therapeutics$9.14M6.89-$129.77M-$0.96N/ALENZ Therapeutics$20.99M9.93-$82.13M-$3.60N/A Does the media refer more to TCRX or LENZ? In the previous week, LENZ Therapeutics had 11 more articles in the media than TScan Therapeutics. MarketBeat recorded 11 mentions for LENZ Therapeutics and 0 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 0.00 beat LENZ Therapeutics' score of -0.54 indicating that TScan Therapeutics is being referred to more favorably in the media. Company Overall Sentiment TScan Therapeutics Neutral LENZ Therapeutics Negative SummaryLENZ Therapeutics beats TScan Therapeutics on 10 of the 16 factors compared between the two stocks.How does TScan Therapeutics compare to Inhibikase Therapeutics?Inhibikase Therapeutics (NASDAQ:IKT) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment. Which has more volatility & risk, IKT or TCRX? Inhibikase Therapeutics has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Is IKT or TCRX more profitable? Inhibikase Therapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. Inhibikase Therapeutics' return on equity of -41.31% beat TScan Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Inhibikase TherapeuticsN/A -41.31% -38.98% TScan Therapeutics -1,360.61%-91.94%-50.15% Which has preferable earnings and valuation, IKT or TCRX? Inhibikase Therapeutics has higher earnings, but lower revenue than TScan Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibikase Therapeutics$260K797.26-$48.26M-$0.43N/ATScan Therapeutics$9.14M6.89-$129.77M-$0.96N/A Does the media refer more to IKT or TCRX? In the previous week, Inhibikase Therapeutics had 2 more articles in the media than TScan Therapeutics. MarketBeat recorded 2 mentions for Inhibikase Therapeutics and 0 mentions for TScan Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.00 beat TScan Therapeutics' score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Inhibikase Therapeutics Neutral TScan Therapeutics Neutral Do institutionals & insiders believe in IKT or TCRX? 3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 7.3% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 6.3% of TScan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate IKT or TCRX? Inhibikase Therapeutics presently has a consensus target price of $5.50, indicating a potential upside of 250.32%. TScan Therapeutics has a consensus target price of $6.00, indicating a potential upside of 522.99%. Given TScan Therapeutics' higher probable upside, analysts clearly believe TScan Therapeutics is more favorable than Inhibikase Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibikase Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 4 Strong Buy rating(s) 3.13TScan Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryInhibikase Therapeutics beats TScan Therapeutics on 11 of the 17 factors compared between the two stocks.How does TScan Therapeutics compare to Cartesian Therapeutics?Cartesian Therapeutics (NASDAQ:RNAC) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk. Does the media prefer RNAC or TCRX? In the previous week, Cartesian Therapeutics had 12 more articles in the media than TScan Therapeutics. MarketBeat recorded 12 mentions for Cartesian Therapeutics and 0 mentions for TScan Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.30 beat TScan Therapeutics' score of 0.00 indicating that Cartesian Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cartesian Therapeutics Neutral TScan Therapeutics Neutral Do analysts rate RNAC or TCRX? Cartesian Therapeutics currently has a consensus price target of $33.00, suggesting a potential upside of 443.66%. TScan Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 522.99%. Given TScan Therapeutics' higher probable upside, analysts clearly believe TScan Therapeutics is more favorable than Cartesian Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cartesian Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67TScan Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do institutionals and insiders hold more shares of RNAC or TCRX? 87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 37.2% of Cartesian Therapeutics shares are held by company insiders. Comparatively, 6.3% of TScan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, RNAC or TCRX? Cartesian Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Is RNAC or TCRX more profitable? TScan Therapeutics has a net margin of -1,360.61% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat TScan Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cartesian Therapeutics-8,550.65% N/A -28.25% TScan Therapeutics -1,360.61%-91.94%-50.15% Which has stronger valuation & earnings, RNAC or TCRX? TScan Therapeutics has higher revenue and earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCartesian Therapeutics$2.80M63.69-$130.30M-$5.90N/ATScan Therapeutics$9.14M6.89-$129.77M-$0.96N/A SummaryCartesian Therapeutics beats TScan Therapeutics on 9 of the 16 factors compared between the two stocks.How does TScan Therapeutics compare to Voyager Therapeutics?Voyager Therapeutics (NASDAQ:VYGR) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations. Do institutionals & insiders have more ownership in VYGR or TCRX? 48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is VYGR or TCRX more profitable? Voyager Therapeutics has a net margin of -319.61% compared to TScan Therapeutics' net margin of -1,360.61%. Voyager Therapeutics' return on equity of -55.97% beat TScan Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Voyager Therapeutics-319.61% -55.97% -43.12% TScan Therapeutics -1,360.61%-91.94%-50.15% Which has better earnings & valuation, VYGR or TCRX? Voyager Therapeutics has higher revenue and earnings than TScan Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVoyager Therapeutics$40.37M5.21-$119.72M-$1.97N/ATScan Therapeutics$9.14M6.89-$129.77M-$0.96N/A Do analysts recommend VYGR or TCRX? Voyager Therapeutics currently has a consensus target price of $16.50, suggesting a potential upside of 374.14%. TScan Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 522.99%. Given TScan Therapeutics' higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than Voyager Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Voyager Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75TScan Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more volatility and risk, VYGR or TCRX? Voyager Therapeutics has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Does the media refer more to VYGR or TCRX? In the previous week, Voyager Therapeutics had 2 more articles in the media than TScan Therapeutics. MarketBeat recorded 2 mentions for Voyager Therapeutics and 0 mentions for TScan Therapeutics. Voyager Therapeutics' average media sentiment score of 0.27 beat TScan Therapeutics' score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Voyager Therapeutics Neutral TScan Therapeutics Neutral SummaryVoyager Therapeutics beats TScan Therapeutics on 11 of the 17 factors compared between the two stocks. Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRX vs. The Competition ExportMetricTScan TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.94M$3.25B$6.25B$12.10BDividend YieldN/A2.33%2.80%5.32%P/E Ratio-1.0018.7020.6025.11Price / Sales6.89278.20577.4291.29Price / CashN/A55.2727.4837.30Price / Book0.456.579.686.60Net Income-$129.77M$24.30M$3.55B$335.60M7 Day Performance-16.25%-3.56%-2.07%-2.03%1 Month Performance-19.07%-7.86%-3.90%-1.90%1 Year Performance-22.33%51.80%29.37%27.35% TScan Therapeutics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRXTScan Therapeutics3.3062 of 5 stars$0.96-3.7%$6.00+523.0%-19.4%$62.94M$9.14MN/A100FHTXFoghorn Therapeutics2.9747 of 5 stars$4.36+0.7%$11.13+155.2%-13.8%$255.98M$30.91MN/A120LENZLENZ Therapeutics2.496 of 5 stars$8.11-18.9%$31.00+282.4%-74.3%$255.82M$19.09MN/A110IKTInhibikase Therapeutics2.3388 of 5 stars$1.94-4.7%$5.50+184.2%N/A$255.54MN/AN/A6Positive NewsEarnings ReportRNACCartesian Therapeutics3.1866 of 5 stars$8.61+0.9%$33.00+283.3%-32.8%$251.99M$2.80MN/A64 Related Companies and Tools Related Companies Foghorn Therapeutics Competitors LENZ Therapeutics Competitors Inhibikase Therapeutics Competitors Cartesian Therapeutics Competitors Voyager Therapeutics Competitors Fate Therapeutics Competitors Adherex Technologies Competitors Sagimet Biosciences Competitors Arcturus Therapeutics Competitors I-Mab Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TCRX) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
